Načítá se...
LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma
Neratinib is an orally available tyrosine kinase inhibitor targeting HER2 (ERBB2) and EGFR (ERBB). It is being clinically evaluated for the treatment of breast and other solid tumors types as a single agent or in combination with other chemotherapies. In support of several phase I/II clinical trials...
Uloženo v:
| Vydáno v: | J Pharm Biomed Anal |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5183482/ https://ncbi.nlm.nih.gov/pubmed/27907855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpba.2016.11.035 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|